BioLine RX LtdNASDAQ:BLRX
- LAST PRICE0.7183
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots0.7000/ 1
- Ask / Lots0.7250/ 1
- Open / Previous Close0.7000 / 0.7183
- Day Range
- 52 Week Range
- Volume232,814
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | BLRX |
|---|---|---|
| 09:32 ET | 2929 | 0.7 |
| 09:36 ET | 300 | 0.7197 |
| 09:38 ET | 150 | 0.7098 |
| 09:43 ET | 200 | 0.7042 |
| 09:45 ET | 250 | 0.7 |
| 09:48 ET | 13520 | 0.7196 |
| 09:52 ET | 1100 | 0.7098 |
| 09:56 ET | 200 | 0.7001 |
| 09:57 ET | 500 | 0.7002 |
| 09:59 ET | 3538 | 0.701 |
| 10:01 ET | 1172 | 0.701 |
| 10:08 ET | 400 | 0.701 |
| 10:14 ET | 1000 | 0.6899 |
| 10:15 ET | 10600 | 0.6812 |
| 10:17 ET | 180 | 0.69789 |
| 10:19 ET | 2200 | 0.6808 |
| 10:21 ET | 100 | 0.6807 |
| 10:26 ET | 1000 | 0.6807 |
| 10:32 ET | 346 | 0.6807 |
| 10:35 ET | 2300 | 0.6811 |
| 10:48 ET | 100 | 0.682 |
| 10:53 ET | 120 | 0.6979 |
| 10:55 ET | 11100 | 0.6811 |
| 10:57 ET | 115 | 0.6979 |
| 11:04 ET | 2600 | 0.6895 |
| 11:09 ET | 4120 | 0.6979 |
| 11:13 ET | 1645 | 0.6813 |
| 11:15 ET | 100 | 0.681201 |
| 11:20 ET | 100 | 0.6813 |
| 11:29 ET | 4900 | 0.6896 |
| 11:38 ET | 7973 | 0.6979 |
| 11:42 ET | 1600 | 0.69 |
| 11:44 ET | 5387 | 0.6978 |
| 11:45 ET | 500 | 0.697 |
| 11:49 ET | 600 | 0.6971 |
| 11:54 ET | 111 | 0.6979 |
| 11:56 ET | 100 | 0.6965 |
| 11:58 ET | 2030 | 0.695 |
| 12:00 ET | 4599 | 0.7085 |
| 12:02 ET | 111 | 0.7018 |
| 12:05 ET | 300 | 0.7 |
| 12:07 ET | 100 | 0.7 |
| 12:09 ET | 200 | 0.7085 |
| 12:14 ET | 2150 | 0.7153 |
| 12:16 ET | 900 | 0.716 |
| 12:18 ET | 2000 | 0.7186 |
| 12:21 ET | 5223 | 0.7174 |
| 12:23 ET | 1369 | 0.712838 |
| 12:25 ET | 12957 | 0.7151 |
| 12:27 ET | 6174 | 0.7128 |
| 12:30 ET | 1000 | 0.712399 |
| 12:34 ET | 9196 | 0.7115 |
| 12:36 ET | 1700 | 0.7115 |
| 12:39 ET | 27751 | 0.7097 |
| 12:41 ET | 1100 | 0.7127 |
| 12:45 ET | 300 | 0.706349 |
| 12:54 ET | 334 | 0.7001 |
| 01:01 ET | 1600 | 0.7099 |
| 01:03 ET | 550 | 0.709999 |
| 01:10 ET | 328 | 0.705 |
| 01:28 ET | 500 | 0.7021 |
| 01:46 ET | 1272 | 0.703837 |
| 01:51 ET | 1119 | 0.7024 |
| 02:09 ET | 355 | 0.707673 |
| 02:11 ET | 2450 | 0.702 |
| 02:42 ET | 22009 | 0.72 |
| 02:45 ET | 143 | 0.711 |
| 02:58 ET | 500 | 0.72 |
| 03:21 ET | 4125 | 0.7105 |
| 03:27 ET | 800 | 0.702 |
| 03:38 ET | 1811 | 0.7023 |
| 03:41 ET | 9200 | 0.7024 |
| 03:50 ET | 100 | 0.7187 |
| 03:52 ET | 100 | 0.7025 |
| 03:54 ET | 200 | 0.7185 |
| 03:56 ET | 1400 | 0.7027 |
| 03:57 ET | 387 | 0.7071 |
| 03:59 ET | 3472 | 0.7183 |
Yesterday
Apr 17, 2024
DJ BioLine RX Price Target Maintained With a $21.00/Share by HC Wainwright & Co., from 1:44PM ET on Wednesday Apr 17, 2024 by Dow Jones
1:44PM ET on Wednesday Apr 17, 2024 by Dow JonesBioLineRx Announces Poster Presentation on Apheresis Center Efficiency and CXCR4 Antagonists including APHEXDA(R) (motixafortide) in Patients with Multiple Myeloma at the ASFA 2024 Annual Meeting, from 7:00AM ET on Wednesday Apr 17, 2024 by Dow Jones
7:00AM ET on Wednesday Apr 17, 2024 by Dow Jones
Apr 10, 2024
BioLineRx Accesses Second Tranche of $20 Million Under Previously Announced $40 Million Non-Dilutive Debt Financing Agreement, from 7:00AM ET on Wednesday Apr 10, 2024 by Dow Jones
7:00AM ET on Wednesday Apr 10, 2024 by Dow JonesPress Release: BioLineRx Accesses Second Tranche of $20 Million Under Previously Announced $40 Million Non-Dilutive Debt Financing Agreement, from 7:00AM ET on Wednesday Apr 10, 2024 by Dow Jones
7:00AM ET on Wednesday Apr 10, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
BioLine RX Ltd | 48.8M | -0.8x | --- |
Aeterna Zentaris Inc | 38.3M | -0.6x | --- |
HCW Biologics Inc | 50.3M | -1.8x | --- |
Palatin Technologies Inc | 34.0M | -0.8x | --- |
Evogene Ltd | 35.9M | -1.3x | --- |
Correlate Energy Corp | 50.2M | -3.5x | --- |
Company Information
BioLine RX Ltd is an Israel-based clinical-stage biopharmaceutical company focused on oncology. The Company is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The Company is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment.
Contact Information
- Headquarters
- Modi'in Technology Park 2 HaMa'ayan StreetMODIIN, Israel 7177871
- Phone
- ---
- Fax
- ---
Executives
- Chairman of the Board
- Aharon Schwartz
- Chief Executive Officer
- Philip Serlin
- Chief Financial Officer
- Mali Zeevi
- Vice President - Development
- Ella Sorani
- Vice President-Clinical & Medical Affairs
- Abi Vainstein-Haras
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $48.8M |
|---|---|
Revenue (TTM) | $4.8M |
Shares Outstanding | 79.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.52 |
EPS | $-0.95 |
Book Value | $0.18 |
P/E Ratio | -0.8x |
Price/Sales (TTM) | 10.2 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -1,035.29% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
